Antibiotic therapy in hematologic patients, often weak and susceptible to a wide range of infections, particularly nosocomial infections derived from long hospitalization periods, is a challenging issue. This paper presents ESBL-producing strains isolated from such hematologic patients treated at the Amazon Hematology and Hemotherapy Foundation (HEMOAM) in the Brazilian Amazon Region to identify the ESBL genes carried by them as well as the susceptibility to 11 antimicrobial agents using the E-test method. All gram-negative strains were tested for extended-spectrum-beta-lactamases (ESBLs), where: (12/17) strains carried ESBL; among these, (8/12) isolates carried bla TEM , bla CTX-M , bla OXA , bla SHV genes, (1/12) bla TEM gene and (3/12) bla TEM , bla CTX-M, bla OXA genes. Antibiotic resistance was found in (15/17) of the isolates for tetracycline, (12/17) for ciprofloxacin, (1/17) resistance for cefoxitin and chloramphenicol, (1/17) for amikacin and (3/17) cefepime. This research showed the presence of gram-negative ESBLproducing bacteria infecting hematologic patients in HEMOAM. These strains carried the bla TEM, bla SHV , bla CTX-M and bla OXA genes and were resistant to different antibiotics used in the treatment. This finding was based on a period of 13 months, during which clinical samples from specific populations were obtained. Therefore, caution is required when generalizing the results that must be based on posological orientations and new breakpoints for disk diffusion and microdilution published by CLSI 2010.
INTRODUCTION
Extended-spectrum beta-lactamases (ESBL) are enzymes produced by gram-negative bacteria such as Klebsiella pneumoniae and Escherichia coli (24) as well as by species from other genera, such as Enterobacter sp., Salmonella sp., Proteus sp., Serratia marcescens, Shigella dysenteriae, Pseudomonas aeruginosa, and Burkholderia cepacia (2, 3, 31, 26) .
ESBLs originate from punctual genetic mutations in the active sites of the TEM-1, TEM-2, and SHV-1 enzymes (3, 10, 12, 31, 19, 23, 26, 34) , which enable the hydrolysis of extended-spectrum cephalosporins, monobactams, penicillins. (2, 3, 5, 9, 11, 12, 27, 30) . However, these plasmid mediated enzymes have their activity inhibited by clavulanic acid, tazobactam and sulbactam. Another important epidemiological characteristic is the possibility of these enzymes being transferred to other species via plasmids or transposons (2, 3, 5, 6, 9, 11, 12, 21, 27, 28, 30, 34) .
The emergence of ESBL-producing bacteria, responsible for infectious processes with high levels of morbidity and mortality has complicated the therapeutic options available for elderly, immunocompromised, and debilitated individuals (4, 31) . The prevalence of ESBLs among clinical isolates varies according to countries and institutions (31) . In the United States, the presence of these enzymes among
Enterobacteriaceae has increased from 0% to 25%, with a national average of 3%, whereas the percentage of Klebsiella sp. has demonstrated an increased resistance from 5% to 10% to ceftazidime (6) .
In other countries, such as Switzerland, the frequency of ESBL-producing bacteria varies from 3% to 8%, whereas it is 34% in Portugal, 4.8% in Korea, 8.5% in Taiwan, 12% in Hong Kong, and 58% in Turkey. In Latin America, studies have reported frequencies ranging from 30% to 60% (6, 21 This study therefore aimed to detect ESBL-producing strains isolated from such hematologic patients treated at the HEMOAM in the Brazilian Amazon region to identify the ESBL genes carried by them and susceptibility to 11
antimicrobial agents using the E-test method.
MATERIALS AND METHODS
The study was approved by the HEMOAM Ethics Committee (Approval number 170 CAAE-0005.0.112.000-06 -Version 003/06). An informed consent was obtained from each patient before specimens were collected and the results were used for the management of each respective patient.
We conducted a descriptive cross-sectional study USA) with a product size around 900 bp, were performed to confirm genus and species (17) .
The sequence analysis of the 16S rRNA region was compared with GenBank data using BLAST search with the MegaBLAST algorithm for identifying high-similarity sequences. The sequences with the highest levels of similarity were considered as being consistent for species identified by the biochemical tests.
The antibiotics E-test ® strips representing common drugs used in the treatment of suspected gram-negative bacterial infections in our hospital were chosen for antimicrobial testing. ESBL isolates were preserved for future molecular analysis.
PCR amplification for the detection of chromosomal betalactamase resistance AmpC type in Pseudomonas spp. isolates
was not included in our study.
The Polimerase Chain Reaction (PCR) assay to amplification and detection of the bla TEM, bla SHV , bla CTX-M and bla OXA was carried out in a final volume reaction of 25µl using
bla OXA -R and 5µl of plasmidial DNA. Cycling parameters were previously described ( Table 2 ). The amplified products obtained have not been sequenced up to the present moment. Hypofibrinogenemia + hemophilia (2/9), Thalassemia (1/9), aplastic anemia (1/9), thrombocytopenic idiopathic purpura (1/9), acute hemolytic anemia (1/9), lymphoma (1/9), unidentified leucopenic disease (1/9), myelodysplastic syndrome (1/9) Beta-lactamase-producing bacteria 
to longer hospital stay and prolonged therapy (1, 29) .
Furthermore, hematologic patients often undergo chemotherapy, which can lead to an immunodeficient status and leave these patients susceptible to a wide range of infections (32, 33) . This is particularly important with respect to nosocomial infection in the hospital environment, which can elevate the risks of mortality and morbidity, mainly in the case of infections caused by ESBL-producing bacteria.
In our study, the most frequent ESBLs-producing bacteria were E. coli, B. cepacia, Serratia spp., and Pseudomonas spp.
In addition, ESBL-producing strains of E. coli and K. The detection of ESBL enzymes is very important, because according to CLSI M100-S17 and M100-S18 (25, 27) criteria, these organisms should be reported as resistant to all extended-spectrum beta-lactam antibiotics, regardless of their susceptibility test results. Currently, according to CLSI M100-S20, new interpretive criteria are available for routine ESBL testing (1, 25, 27) .
The reduced sensitivity to cephalosporins detected in E.
coli strains in this study might be due to the variations in substratum preference, the differing accuracy between tests for enzyme detection, weak inhibition by clavulanic acid, or different combined resistance mechanisms that led either to reduced or no sensitivity (26, 35 (12, 16, 25, 39) .
The control of bacterial resistance is directly related to the Beta-lactamase-producing bacteria detection of this mechanism through laboratory and molecular tests as well as the implementation of rational use of antibiotics in hospitals (26, 39 (14) .
The prevalence of ESBL production in Enterobacteriaceae in France (18) This research showed the presence of gram-negative ESBL-producing bacteria infecting hematologic patients in HEMOAM. These strains carried the bla TEM, bla SHV , bla CTX-M and bla OXA genes and were resistant to different antibiotics used in the treatment. It is necessary to perform screening and confirmatory test for phenotypic detection of these strains in a routine laboratory to avoid health care failure.
